[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fUTSsBJV_JVOpBPVNRNWsdERDWkSHcI0YFW7Y_qpuXwI":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":32,"phaseBuckets":43,"rows":50},"University of Pecs",[4],97,false,17,7,30352,4,73,[14,17,19,21,23,26,28,30],{"name":15,"count":16},"COVID-19",5,{"name":18,"count":11},"Knee Osteoarthritis",{"name":20,"count":11},"Physical Inactivity",{"name":22,"count":11},"Sepsis",{"name":24,"count":25},"Septic Shock",3,{"name":27,"count":25},"Diabetes Mellitus, Type 2",{"name":29,"count":25},"Diabetes Mellitus",{"name":31,"count":25},"Quality of Life",[33,38],{"nctId":34,"briefTitle":35,"date":36,"intervention":37},"NCT05100719","The Role of Irritable Bowel Syndrome in Lactose Intolerance (LION)","2026-09","alverine-citrate + simethicone and lactase",{"nctId":39,"briefTitle":40,"date":41,"intervention":42},"NCT05060731","Iron Supplementation in Upper Non-variceal Gastrointestinal Bleeding","2027-12-31","Oral iron supplementation",[44,45,46,47,48,49],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[51,78,96,121,139,164,195,213,240,258,286,304,330,359,377,401,426,452,480,498,522,547,572,599,624,650,668,696,714,732,750,774,798,825,843,861,890,908,926,944,971],{"intervention":42,"totalTrials":52,"cells":53},1,{"EARLY_PHASE1":54,"PHASE1":57,"PHASE2":59,"PHASE3":61,"PHASE4":63,"NA":76},{"trials":55,"activeCount":56},[],0,{"trials":58,"activeCount":56},[],{"trials":60,"activeCount":56},[],{"trials":62,"activeCount":56},[],{"trials":64,"activeCount":52,"soonestReadout":41},[65],{"nctId":39,"briefTitle":40,"status":66,"phases":67,"primaryCompletion":41,"completion":68,"start":69,"enrollment":70,"conditions":71,"interventions":74},"NOT_YET_RECRUITING",[48],"2028-02-01","2025-09-01",570,[72,73],"GastroIntestinal Bleeding","Anemia",[42,75],"Intravenous iron supplementation",{"trials":77,"activeCount":56},[],{"intervention":75,"totalTrials":52,"cells":79},{"EARLY_PHASE1":80,"PHASE1":82,"PHASE2":84,"PHASE3":86,"PHASE4":88,"NA":94},{"trials":81,"activeCount":56},[],{"trials":83,"activeCount":56},[],{"trials":85,"activeCount":56},[],{"trials":87,"activeCount":56},[],{"trials":89,"activeCount":52,"soonestReadout":41},[90],{"nctId":39,"briefTitle":40,"status":66,"phases":91,"primaryCompletion":41,"completion":68,"start":69,"enrollment":70,"conditions":92,"interventions":93},[48],[72,73],[42,75],{"trials":95,"activeCount":56},[],{"intervention":37,"totalTrials":52,"cells":97},{"EARLY_PHASE1":98,"PHASE1":100,"PHASE2":102,"PHASE3":104,"PHASE4":106,"NA":108},{"trials":99,"activeCount":56},[],{"trials":101,"activeCount":56},[],{"trials":103,"activeCount":56},[],{"trials":105,"activeCount":56},[],{"trials":107,"activeCount":56},[],{"trials":109,"activeCount":52,"soonestReadout":36},[110],{"nctId":34,"briefTitle":35,"status":66,"phases":111,"primaryCompletion":36,"completion":112,"start":113,"enrollment":114,"conditions":115,"interventions":119},[49],"2026-12","2022-09",200,[116,117,118],"Irritable Bowel Syndrome","Lactose Intolerance","Lactose Malabsorption",[37,120],"alverin-citrate + simethicone with placebo",{"intervention":120,"totalTrials":52,"cells":122},{"EARLY_PHASE1":123,"PHASE1":125,"PHASE2":127,"PHASE3":129,"PHASE4":131,"NA":133},{"trials":124,"activeCount":56},[],{"trials":126,"activeCount":56},[],{"trials":128,"activeCount":56},[],{"trials":130,"activeCount":56},[],{"trials":132,"activeCount":56},[],{"trials":134,"activeCount":52,"soonestReadout":36},[135],{"nctId":34,"briefTitle":35,"status":66,"phases":136,"primaryCompletion":36,"completion":112,"start":113,"enrollment":114,"conditions":137,"interventions":138},[49],[116,117,118],[37,120],{"intervention":140,"totalTrials":52,"cells":141},"Vitamin C",{"EARLY_PHASE1":142,"PHASE1":144,"PHASE2":146,"PHASE3":148,"PHASE4":150,"NA":162},{"trials":143,"activeCount":56},[],{"trials":145,"activeCount":56},[],{"trials":147,"activeCount":56},[],{"trials":149,"activeCount":56},[],{"trials":151,"activeCount":56},[152],{"nctId":153,"briefTitle":154,"status":155,"phases":156,"primaryCompletion":157,"completion":157,"start":158,"enrollment":159,"conditions":160,"interventions":161},"NCT06152458","Blessing or Curse? Combined Vitamin Therapy in Non Viral Septic Shock.","COMPLETED",[48],"2020-03-01","2019-01-01",43,[24],[140],{"trials":163,"activeCount":56},[],{"intervention":165,"totalTrials":52,"cells":166},"Iodoform",{"EARLY_PHASE1":167,"PHASE1":169,"PHASE2":171,"PHASE3":173,"PHASE4":175,"NA":193},{"trials":168,"activeCount":56},[],{"trials":170,"activeCount":56},[],{"trials":172,"activeCount":56},[],{"trials":174,"activeCount":56},[],{"trials":176,"activeCount":56},[177],{"nctId":178,"briefTitle":179,"status":180,"phases":181,"primaryCompletion":182,"completion":183,"start":184,"enrollment":185,"conditions":186,"interventions":191},"NCT03741894","Examination of the Prevention and Treatment Modalities of Alveolitis in Relation With Impacted Teeth Surgery","UNKNOWN",[48],"2020-09-30","2021-09-30","2018-09-01",50,[187,188,189,190],"Alveolitis of Jaw","Alveoli, Teeth; Inflammation","Dry Socket","Impacted Third Molar Tooth",[165,192],"Chlorhexidine",{"trials":194,"activeCount":56},[],{"intervention":192,"totalTrials":52,"cells":196},{"EARLY_PHASE1":197,"PHASE1":199,"PHASE2":201,"PHASE3":203,"PHASE4":205,"NA":211},{"trials":198,"activeCount":56},[],{"trials":200,"activeCount":56},[],{"trials":202,"activeCount":56},[],{"trials":204,"activeCount":56},[],{"trials":206,"activeCount":56},[207],{"nctId":178,"briefTitle":179,"status":180,"phases":208,"primaryCompletion":182,"completion":183,"start":184,"enrollment":185,"conditions":209,"interventions":210},[48],[187,188,189,190],[165,192],{"trials":212,"activeCount":56},[],{"intervention":214,"totalTrials":52,"cells":215},"Clopidogrel reloading",{"EARLY_PHASE1":216,"PHASE1":218,"PHASE2":220,"PHASE3":222,"PHASE4":224,"NA":238},{"trials":217,"activeCount":56},[],{"trials":219,"activeCount":56},[],{"trials":221,"activeCount":56},[],{"trials":223,"activeCount":56},[],{"trials":225,"activeCount":56},[226],{"nctId":227,"briefTitle":228,"status":155,"phases":229,"primaryCompletion":230,"completion":231,"start":232,"enrollment":233,"conditions":234,"interventions":236},"NCT01493999","Prasugrel Versus Clopidogrel to TREAT High Platelet Reactivity",[48],"2013-01","2013-04","2011-09",147,[235],"Acute Coronary Syndrome",[214,237],"Prasugrel",{"trials":239,"activeCount":56},[],{"intervention":237,"totalTrials":52,"cells":241},{"EARLY_PHASE1":242,"PHASE1":244,"PHASE2":246,"PHASE3":248,"PHASE4":250,"NA":256},{"trials":243,"activeCount":56},[],{"trials":245,"activeCount":56},[],{"trials":247,"activeCount":56},[],{"trials":249,"activeCount":56},[],{"trials":251,"activeCount":56},[252],{"nctId":227,"briefTitle":228,"status":155,"phases":253,"primaryCompletion":230,"completion":231,"start":232,"enrollment":233,"conditions":254,"interventions":255},[48],[235],[214,237],{"trials":257,"activeCount":56},[],{"intervention":259,"totalTrials":52,"cells":260},"Plavix",{"EARLY_PHASE1":261,"PHASE1":263,"PHASE2":265,"PHASE3":267,"PHASE4":269,"NA":284},{"trials":262,"activeCount":56},[],{"trials":264,"activeCount":56},[],{"trials":266,"activeCount":56},[],{"trials":268,"activeCount":56},[],{"trials":270,"activeCount":56},[271],{"nctId":272,"briefTitle":273,"status":155,"phases":274,"primaryCompletion":275,"completion":276,"start":277,"enrollment":278,"conditions":279,"interventions":282},"NCT01147133","Comparison of Generic and Original Formulation of Clopidogrel",[48],"2010-04","2010-05","2009-11",75,[280,281],"Coronary Heart Disease","Percutaneous Coronary Intervention",[259,283],"Kardogrel",{"trials":285,"activeCount":56},[],{"intervention":283,"totalTrials":52,"cells":287},{"EARLY_PHASE1":288,"PHASE1":290,"PHASE2":292,"PHASE3":294,"PHASE4":296,"NA":302},{"trials":289,"activeCount":56},[],{"trials":291,"activeCount":56},[],{"trials":293,"activeCount":56},[],{"trials":295,"activeCount":56},[],{"trials":297,"activeCount":56},[298],{"nctId":272,"briefTitle":273,"status":155,"phases":299,"primaryCompletion":275,"completion":276,"start":277,"enrollment":278,"conditions":300,"interventions":301},[48],[280,281],[259,283],{"trials":303,"activeCount":56},[],{"intervention":305,"totalTrials":52,"cells":306},"Remdesivir-HU",{"EARLY_PHASE1":307,"PHASE1":309,"PHASE2":311,"PHASE3":313,"PHASE4":326,"NA":328},{"trials":308,"activeCount":56},[],{"trials":310,"activeCount":56},[],{"trials":312,"activeCount":56},[],{"trials":314,"activeCount":56},[315],{"nctId":316,"briefTitle":317,"status":180,"phases":318,"primaryCompletion":319,"completion":320,"start":321,"enrollment":322,"conditions":323,"interventions":325},"NCT04610541","REMdesivir-HU Clinical Study and Severe Covid-19 Patients",[47],"2021-10-30","2021-11-30","2020-10-12",2000,[324],"SARS-CoV-2 Infection",[305],{"trials":327,"activeCount":56},[],{"trials":329,"activeCount":56},[],{"intervention":331,"totalTrials":52,"cells":332},"clopidogrel",{"EARLY_PHASE1":333,"PHASE1":335,"PHASE2":337,"PHASE3":339,"PHASE4":355,"NA":357},{"trials":334,"activeCount":56},[],{"trials":336,"activeCount":56},[],{"trials":338,"activeCount":56},[],{"trials":340,"activeCount":56},[341],{"nctId":342,"briefTitle":343,"status":344,"phases":345,"primaryCompletion":346,"completion":347,"start":348,"enrollment":349,"conditions":350,"interventions":353},"NCT00638326","Doubling the Maintenance Dose of Clopidogrel in Patients With High On-Clopidogrel Platelet Reactivity","TERMINATED",[47],"2009-09","2010-03","2008-03",500,[351,352],"Stable Angina Pectoris","Ad Hoc Percutaneous Coronary Intervention",[331,354],"clopidogrel plus placebo",{"trials":356,"activeCount":56},[],{"trials":358,"activeCount":56},[],{"intervention":354,"totalTrials":52,"cells":360},{"EARLY_PHASE1":361,"PHASE1":363,"PHASE2":365,"PHASE3":367,"PHASE4":373,"NA":375},{"trials":362,"activeCount":56},[],{"trials":364,"activeCount":56},[],{"trials":366,"activeCount":56},[],{"trials":368,"activeCount":56},[369],{"nctId":342,"briefTitle":343,"status":344,"phases":370,"primaryCompletion":346,"completion":347,"start":348,"enrollment":349,"conditions":371,"interventions":372},[47],[351,352],[331,354],{"trials":374,"activeCount":56},[],{"trials":376,"activeCount":56},[],{"intervention":378,"totalTrials":52,"cells":379},"Favipiravir",{"EARLY_PHASE1":380,"PHASE1":382,"PHASE2":384,"PHASE3":386,"PHASE4":397,"NA":399},{"trials":381,"activeCount":56},[],{"trials":383,"activeCount":56},[],{"trials":385,"activeCount":56},[],{"trials":387,"activeCount":56},[388],{"nctId":389,"briefTitle":390,"status":155,"phases":391,"primaryCompletion":392,"completion":392,"start":393,"enrollment":394,"conditions":395,"interventions":396},"NCT04600999","Clinical Trial of Favipiravir Treatment of Patients With COVID-19",[47],"2020-12-28","2020-10-07",14,[324],[378],{"trials":398,"activeCount":56},[],{"trials":400,"activeCount":56},[],{"intervention":402,"totalTrials":52,"cells":403},"pramipexole",{"EARLY_PHASE1":404,"PHASE1":406,"PHASE2":408,"PHASE3":410,"PHASE4":422,"NA":424},{"trials":405,"activeCount":56},[],{"trials":407,"activeCount":56},[],{"trials":409,"activeCount":56},[],{"trials":411,"activeCount":56},[412],{"nctId":413,"briefTitle":414,"status":415,"phases":416,"primaryCompletion":417,"completion":417,"start":418,"enrollment":56,"conditions":419,"interventions":421},"NCT01441284","Efficacy of Pramipexole Extended Release in the Treatment of Essential Tremor","WITHDRAWN",[47],"2018-12","2017-12",[420],"Essential Tremor",[402],{"trials":423,"activeCount":56},[],{"trials":425,"activeCount":56},[],{"intervention":427,"totalTrials":52,"cells":428},"Standard medical therapy",{"EARLY_PHASE1":429,"PHASE1":431,"PHASE2":433,"PHASE3":435,"PHASE4":448,"NA":450},{"trials":430,"activeCount":56},[],{"trials":432,"activeCount":56},[],{"trials":434,"activeCount":56},[],{"trials":436,"activeCount":56},[437],{"nctId":438,"briefTitle":439,"status":440,"phases":441,"primaryCompletion":442,"completion":443,"start":444,"enrollment":445,"conditions":446,"interventions":447},"NCT04742764","Extracorporal Cytokin Removal in Septic Shock: a Prospective, Randomized, Multicenter Clinical Trial","SUSPENDED",[47],"2026-10-31","2027-10-31","2024-01-01",135,[24],[427],{"trials":449,"activeCount":56},[],{"trials":451,"activeCount":56},[],{"intervention":453,"totalTrials":52,"cells":454},"Fecal filtrate transplantation",{"EARLY_PHASE1":455,"PHASE1":457,"PHASE2":459,"PHASE3":461,"PHASE4":476,"NA":478},{"trials":456,"activeCount":56},[],{"trials":458,"activeCount":56},[],{"trials":460,"activeCount":56},[],{"trials":462,"activeCount":56},[463],{"nctId":464,"briefTitle":465,"status":180,"phases":466,"primaryCompletion":467,"completion":468,"start":469,"enrollment":470,"conditions":471,"interventions":474},"NCT04960306","Fecal Filtrate as a Treatment Option of Multiple Recurrent Clostridioides Difficile Infection",[47],"2024-12-01","2025-12-01","2023-11-01",238,[472,473],"Clostridium Difficile Infection","Recurrent Clostridium Difficile Infection",[453,475],"Conventional fecal microbiota transplantation",{"trials":477,"activeCount":56},[],{"trials":479,"activeCount":56},[],{"intervention":475,"totalTrials":52,"cells":481},{"EARLY_PHASE1":482,"PHASE1":484,"PHASE2":486,"PHASE3":488,"PHASE4":494,"NA":496},{"trials":483,"activeCount":56},[],{"trials":485,"activeCount":56},[],{"trials":487,"activeCount":56},[],{"trials":489,"activeCount":56},[490],{"nctId":464,"briefTitle":465,"status":180,"phases":491,"primaryCompletion":467,"completion":468,"start":469,"enrollment":470,"conditions":492,"interventions":493},[47],[472,473],[453,475],{"trials":495,"activeCount":56},[],{"trials":497,"activeCount":56},[],{"intervention":499,"totalTrials":52,"cells":500},"Favipiravir HU 200 mg hard",{"EARLY_PHASE1":501,"PHASE1":503,"PHASE2":505,"PHASE3":516,"PHASE4":518,"NA":520},{"trials":502,"activeCount":56},[],{"trials":504,"activeCount":56},[],{"trials":506,"activeCount":56},[507],{"nctId":508,"briefTitle":509,"status":344,"phases":510,"primaryCompletion":511,"completion":511,"start":512,"enrollment":52,"conditions":513,"interventions":515},"NCT04940871","Study to Assess the Efficacy and Safety of Favipiravir-HU",[46],"2021-11-29","2021-11-25",[514],"Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)",[499],{"trials":517,"activeCount":56},[],{"trials":519,"activeCount":56},[],{"trials":521,"activeCount":56},[],{"intervention":523,"totalTrials":52,"cells":524},"ranibizumab",{"EARLY_PHASE1":525,"PHASE1":527,"PHASE2":529,"PHASE3":541,"PHASE4":543,"NA":545},{"trials":526,"activeCount":56},[],{"trials":528,"activeCount":56},[],{"trials":530,"activeCount":56},[531],{"nctId":532,"briefTitle":533,"status":180,"phases":534,"primaryCompletion":232,"completion":232,"start":535,"enrollment":536,"conditions":537,"interventions":540},"NCT01123564","Efficacy and Safety of Lucentis for Clinically Significant Macular Edema Secondary to Central Retinal Vein Occlusion",[46],"2009-08",40,[538,539],"Retinal Vein Occlusion","Macular Edema",[523],{"trials":542,"activeCount":56},[],{"trials":544,"activeCount":56},[],{"trials":546,"activeCount":56},[],{"intervention":548,"totalTrials":52,"cells":549},"Para-Tyrosine supplementation",{"EARLY_PHASE1":550,"PHASE1":552,"PHASE2":554,"PHASE3":566,"PHASE4":568,"NA":570},{"trials":551,"activeCount":56},[],{"trials":553,"activeCount":56},[],{"trials":555,"activeCount":56},[556],{"nctId":557,"briefTitle":558,"status":440,"phases":559,"primaryCompletion":560,"completion":561,"start":562,"enrollment":563,"conditions":564,"interventions":565},"NCT03278730","Efficacy of Para-Tyrosine Supplementation on the Survival and Clinical Outcome in Patients With Sepsis",[46],"2027-01-01","2027-02-28","2027-01",296,[22],[548],{"trials":567,"activeCount":56},[],{"trials":569,"activeCount":56},[],{"trials":571,"activeCount":56},[],{"intervention":573,"totalTrials":52,"cells":574},"Human albumin",{"EARLY_PHASE1":575,"PHASE1":589,"PHASE2":591,"PHASE3":593,"PHASE4":595,"NA":597},{"trials":576,"activeCount":56},[577],{"nctId":578,"briefTitle":579,"status":180,"phases":580,"primaryCompletion":581,"completion":582,"start":583,"enrollment":584,"conditions":585,"interventions":588},"NCT03950778","The Effect of Albumin Supplementation on the Inflammatory and Oxidative Stress Markers in Septic Patients",[44],"2021-04-01","2022-04-01","2019-04-01",30,[586,587,22],"Albumin Supplementation","Albumin Therapy",[573],{"trials":590,"activeCount":56},[],{"trials":592,"activeCount":56},[],{"trials":594,"activeCount":56},[],{"trials":596,"activeCount":56},[],{"trials":598,"activeCount":56},[],{"intervention":600,"totalTrials":52,"cells":601},"Influenza vaccine, Immune function",{"EARLY_PHASE1":602,"PHASE1":614,"PHASE2":616,"PHASE3":618,"PHASE4":620,"NA":622},{"trials":603,"activeCount":56},[604],{"nctId":605,"briefTitle":606,"status":155,"phases":607,"primaryCompletion":608,"completion":608,"start":609,"enrollment":610,"conditions":611,"interventions":613},"NCT03833271","The Efficacy of Influenza Vaccine Program in Children With Juvenile Idiopathic Arthritis. A Single Centre Results From Hungary",[44],"2019-09-30","2018-10-28",62,[612],"Juvenile Idiopathic Arthritis",[600],{"trials":615,"activeCount":56},[],{"trials":617,"activeCount":56},[],{"trials":619,"activeCount":56},[],{"trials":621,"activeCount":56},[],{"trials":623,"activeCount":56},[],{"intervention":625,"totalTrials":52,"cells":626},"End-range mobilization",{"EARLY_PHASE1":627,"PHASE1":629,"PHASE2":631,"PHASE3":633,"PHASE4":635,"NA":637},{"trials":628,"activeCount":56},[],{"trials":630,"activeCount":56},[],{"trials":632,"activeCount":56},[],{"trials":634,"activeCount":56},[],{"trials":636,"activeCount":56},[],{"trials":638,"activeCount":56},[639],{"nctId":640,"briefTitle":641,"status":155,"phases":642,"primaryCompletion":643,"completion":644,"start":645,"enrollment":646,"conditions":647,"interventions":648},"NCT04629625","End-range Mobilization on Time Curve of Pressure Pain Threshold",[49],"2021-01-02","2021-05-01","2020-10-10",66,[18],[625,649],"Non end-range mobilization",{"intervention":649,"totalTrials":52,"cells":651},{"EARLY_PHASE1":652,"PHASE1":654,"PHASE2":656,"PHASE3":658,"PHASE4":660,"NA":662},{"trials":653,"activeCount":56},[],{"trials":655,"activeCount":56},[],{"trials":657,"activeCount":56},[],{"trials":659,"activeCount":56},[],{"trials":661,"activeCount":56},[],{"trials":663,"activeCount":56},[664],{"nctId":640,"briefTitle":641,"status":155,"phases":665,"primaryCompletion":643,"completion":644,"start":645,"enrollment":646,"conditions":666,"interventions":667},[49],[18],[625,649],{"intervention":669,"totalTrials":52,"cells":670},"Sevoflurane group A",{"EARLY_PHASE1":671,"PHASE1":673,"PHASE2":675,"PHASE3":677,"PHASE4":679,"NA":681},{"trials":672,"activeCount":56},[],{"trials":674,"activeCount":56},[],{"trials":676,"activeCount":56},[],{"trials":678,"activeCount":56},[],{"trials":680,"activeCount":56},[],{"trials":682,"activeCount":56},[683],{"nctId":684,"briefTitle":685,"status":155,"phases":686,"primaryCompletion":687,"completion":687,"start":688,"enrollment":689,"conditions":690,"interventions":692},"NCT02920749","Study of Anaesthesia Costs and Recovery Profiles",[49],"2016-10","2014-09",120,[691],"Anaesthesia",[669,693,694,695],"Sevoflurane group B","Propofol group C","Propofol group D",{"intervention":693,"totalTrials":52,"cells":697},{"EARLY_PHASE1":698,"PHASE1":700,"PHASE2":702,"PHASE3":704,"PHASE4":706,"NA":708},{"trials":699,"activeCount":56},[],{"trials":701,"activeCount":56},[],{"trials":703,"activeCount":56},[],{"trials":705,"activeCount":56},[],{"trials":707,"activeCount":56},[],{"trials":709,"activeCount":56},[710],{"nctId":684,"briefTitle":685,"status":155,"phases":711,"primaryCompletion":687,"completion":687,"start":688,"enrollment":689,"conditions":712,"interventions":713},[49],[691],[669,693,694,695],{"intervention":694,"totalTrials":52,"cells":715},{"EARLY_PHASE1":716,"PHASE1":718,"PHASE2":720,"PHASE3":722,"PHASE4":724,"NA":726},{"trials":717,"activeCount":56},[],{"trials":719,"activeCount":56},[],{"trials":721,"activeCount":56},[],{"trials":723,"activeCount":56},[],{"trials":725,"activeCount":56},[],{"trials":727,"activeCount":56},[728],{"nctId":684,"briefTitle":685,"status":155,"phases":729,"primaryCompletion":687,"completion":687,"start":688,"enrollment":689,"conditions":730,"interventions":731},[49],[691],[669,693,694,695],{"intervention":695,"totalTrials":52,"cells":733},{"EARLY_PHASE1":734,"PHASE1":736,"PHASE2":738,"PHASE3":740,"PHASE4":742,"NA":744},{"trials":735,"activeCount":56},[],{"trials":737,"activeCount":56},[],{"trials":739,"activeCount":56},[],{"trials":741,"activeCount":56},[],{"trials":743,"activeCount":56},[],{"trials":745,"activeCount":56},[746],{"nctId":684,"briefTitle":685,"status":155,"phases":747,"primaryCompletion":687,"completion":687,"start":688,"enrollment":689,"conditions":748,"interventions":749},[49],[691],[669,693,694,695],{"intervention":751,"totalTrials":52,"cells":752},"SGLT-2 inhibitor",{"EARLY_PHASE1":753,"PHASE1":755,"PHASE2":757,"PHASE3":759,"PHASE4":761,"NA":763},{"trials":754,"activeCount":56},[],{"trials":756,"activeCount":56},[],{"trials":758,"activeCount":56},[],{"trials":760,"activeCount":56},[],{"trials":762,"activeCount":56},[],{"trials":764,"activeCount":56},[765],{"nctId":766,"briefTitle":767,"status":155,"phases":768,"primaryCompletion":769,"completion":769,"start":770,"enrollment":536,"conditions":771,"interventions":773},"NCT06797115","Hydroxyl Free Radical Associated Effects of SGLT-2 Inhibitors in Type 2 Diabetes",[],"2024-06-30","2022-07-18",[772],"T2DM",[751],{"intervention":775,"totalTrials":52,"cells":776},"IL6 Antagonist",{"EARLY_PHASE1":777,"PHASE1":779,"PHASE2":781,"PHASE3":783,"PHASE4":785,"NA":787},{"trials":778,"activeCount":56},[],{"trials":780,"activeCount":56},[],{"trials":782,"activeCount":56},[],{"trials":784,"activeCount":56},[],{"trials":786,"activeCount":56},[],{"trials":788,"activeCount":56},[789],{"nctId":790,"briefTitle":791,"status":180,"phases":792,"primaryCompletion":793,"completion":467,"start":794,"enrollment":584,"conditions":795,"interventions":797},"NCT05218369","Interleukin-6 Antagonists in Critically-ill Covid-19 Patients",[],"2023-12-31","2022-02-06",[15,796],"Critical Illness",[775],{"intervention":799,"totalTrials":52,"cells":800},"Lidocaine brachial plexus block",{"EARLY_PHASE1":801,"PHASE1":803,"PHASE2":805,"PHASE3":807,"PHASE4":809,"NA":811},{"trials":802,"activeCount":56},[],{"trials":804,"activeCount":56},[],{"trials":806,"activeCount":56},[],{"trials":808,"activeCount":56},[],{"trials":810,"activeCount":56},[],{"trials":812,"activeCount":56},[813],{"nctId":814,"briefTitle":815,"status":180,"phases":816,"primaryCompletion":817,"completion":818,"start":819,"enrollment":584,"conditions":820,"interventions":822},"NCT03527836","Plasma Concentration of Lidocaine and Bupivacaine Axillary BPB Mixture Solutions [PCLBAxMix]",[49],"2021-12-17","2022-01-17","2017-03-17",[821],"Arm Injury",[799,823,824],"Bupivacaine brachial plexus block","Mixture brachial plexus block",{"intervention":823,"totalTrials":52,"cells":826},{"EARLY_PHASE1":827,"PHASE1":829,"PHASE2":831,"PHASE3":833,"PHASE4":835,"NA":837},{"trials":828,"activeCount":56},[],{"trials":830,"activeCount":56},[],{"trials":832,"activeCount":56},[],{"trials":834,"activeCount":56},[],{"trials":836,"activeCount":56},[],{"trials":838,"activeCount":56},[839],{"nctId":814,"briefTitle":815,"status":180,"phases":840,"primaryCompletion":817,"completion":818,"start":819,"enrollment":584,"conditions":841,"interventions":842},[49],[821],[799,823,824],{"intervention":824,"totalTrials":52,"cells":844},{"EARLY_PHASE1":845,"PHASE1":847,"PHASE2":849,"PHASE3":851,"PHASE4":853,"NA":855},{"trials":846,"activeCount":56},[],{"trials":848,"activeCount":56},[],{"trials":850,"activeCount":56},[],{"trials":852,"activeCount":56},[],{"trials":854,"activeCount":56},[],{"trials":856,"activeCount":56},[857],{"nctId":814,"briefTitle":815,"status":180,"phases":858,"primaryCompletion":817,"completion":818,"start":819,"enrollment":584,"conditions":859,"interventions":860},[49],[821],[799,823,824],{"intervention":862,"totalTrials":52,"cells":863},"brachial plexus block for LB Group",{"EARLY_PHASE1":864,"PHASE1":866,"PHASE2":868,"PHASE3":870,"PHASE4":872,"NA":874},{"trials":865,"activeCount":56},[],{"trials":867,"activeCount":56},[],{"trials":869,"activeCount":56},[],{"trials":871,"activeCount":56},[],{"trials":873,"activeCount":56},[],{"trials":875,"activeCount":56},[876],{"nctId":877,"briefTitle":878,"status":155,"phases":879,"primaryCompletion":880,"completion":881,"start":882,"enrollment":883,"conditions":884,"interventions":886},"NCT03454789","Comparison of the Onset Times and Durations of Actions of Different Local Anesthetic Mixture Solutions [CODLAM]",[49],"2017-08-15","2017-11-30","2017-01-17",85,[885],"Injury Arm",[862,887,888,889],"brachial plexus block for BS Group","brachial plexus block for LS Group","brachial plexus block for BL Group",{"intervention":887,"totalTrials":52,"cells":891},{"EARLY_PHASE1":892,"PHASE1":894,"PHASE2":896,"PHASE3":898,"PHASE4":900,"NA":902},{"trials":893,"activeCount":56},[],{"trials":895,"activeCount":56},[],{"trials":897,"activeCount":56},[],{"trials":899,"activeCount":56},[],{"trials":901,"activeCount":56},[],{"trials":903,"activeCount":56},[904],{"nctId":877,"briefTitle":878,"status":155,"phases":905,"primaryCompletion":880,"completion":881,"start":882,"enrollment":883,"conditions":906,"interventions":907},[49],[885],[862,887,888,889],{"intervention":888,"totalTrials":52,"cells":909},{"EARLY_PHASE1":910,"PHASE1":912,"PHASE2":914,"PHASE3":916,"PHASE4":918,"NA":920},{"trials":911,"activeCount":56},[],{"trials":913,"activeCount":56},[],{"trials":915,"activeCount":56},[],{"trials":917,"activeCount":56},[],{"trials":919,"activeCount":56},[],{"trials":921,"activeCount":56},[922],{"nctId":877,"briefTitle":878,"status":155,"phases":923,"primaryCompletion":880,"completion":881,"start":882,"enrollment":883,"conditions":924,"interventions":925},[49],[885],[862,887,888,889],{"intervention":889,"totalTrials":52,"cells":927},{"EARLY_PHASE1":928,"PHASE1":930,"PHASE2":932,"PHASE3":934,"PHASE4":936,"NA":938},{"trials":929,"activeCount":56},[],{"trials":931,"activeCount":56},[],{"trials":933,"activeCount":56},[],{"trials":935,"activeCount":56},[],{"trials":937,"activeCount":56},[],{"trials":939,"activeCount":56},[940],{"nctId":877,"briefTitle":878,"status":155,"phases":941,"primaryCompletion":880,"completion":881,"start":882,"enrollment":883,"conditions":942,"interventions":943},[49],[885],[862,887,888,889],{"intervention":945,"totalTrials":52,"cells":946},"Fosfomycin",{"EARLY_PHASE1":947,"PHASE1":949,"PHASE2":951,"PHASE3":953,"PHASE4":955,"NA":957},{"trials":948,"activeCount":56},[],{"trials":950,"activeCount":56},[],{"trials":952,"activeCount":56},[],{"trials":954,"activeCount":56},[],{"trials":956,"activeCount":56},[],{"trials":958,"activeCount":56},[959],{"nctId":960,"briefTitle":961,"status":180,"phases":962,"primaryCompletion":963,"completion":964,"start":965,"enrollment":966,"conditions":967,"interventions":969},"NCT05055544","Bearberry in the Treatment of Cystitis",[49],"2025-10","2025-12","2021-10",504,[968],"Cystitis",[945,970],"Bearberry",{"intervention":970,"totalTrials":52,"cells":972},{"EARLY_PHASE1":973,"PHASE1":975,"PHASE2":977,"PHASE3":979,"PHASE4":981,"NA":983},{"trials":974,"activeCount":56},[],{"trials":976,"activeCount":56},[],{"trials":978,"activeCount":56},[],{"trials":980,"activeCount":56},[],{"trials":982,"activeCount":56},[],{"trials":984,"activeCount":56},[985],{"nctId":960,"briefTitle":961,"status":180,"phases":986,"primaryCompletion":963,"completion":964,"start":965,"enrollment":966,"conditions":987,"interventions":988},[49],[968],[945,970]]